Review: management of Parkinson’s disease

References

• BraakHDel TrediciKRubUde VosRAJansen SteurENBraakEStaging of brain pathology related to sporadic Parkinson’s diseaseNeurobiol Aging200324219721112498954
   PubMed Web of Science ®Google Scholar
• KaufmanMJMadrasBKSevere depletion of cocaine recognition sites associated with the dopamine transporter in Parkinson’s-diseased striatumSynapse19919143491796351
   PubMed Web of Science ®Google Scholar
• NiznikHBFogelEFFassosFFSeemanPThe dopamine transporter is absent in parkinsonian putamen and reduced in the caudate nucleusJ Neurochem19915611921981987318
   PubMed Web of Science ®Google Scholar
• EggersCPedrosaDJKahramanDParkinson subtypes progress differently in clinical course and imaging patternPLoS One2012710e4681323056463
   PubMed Web of Science ®Google Scholar
• RajputAHVollARajputMLRobinsonCARajputACourse in Parkinson disease subtypes: a 39-year clinicopathologic studyNeurology200973320621219620608
   PubMed Web of Science ®Google Scholar
• AshburnAFazakarleyLBallingerCPickeringRMcLellanLDFittonCA randomised controlled trial of a home based exercise programme to reduce the risk of falling among people with Parkinson’s diseaseJ Neurol Neurosurg Psychiatry200778767868417119004
   PubMed Web of Science ®Google Scholar
• CakitBDSaracogluMGencHErdemHRInanLThe effects of incremental speed-dependent treadmill training on postural instability and fear of falling in Parkinson’s diseaseClin Rehabil200721869870517846069
   PubMed Web of Science ®Google Scholar
• EbersbachGEbersbachAEdlerDComparing exercise in Parkinson’s disease – the Berlin LSVT®BIG studyMov Disord201025121902190820669294
   PubMed Web of Science ®Google Scholar
• EllisTde GoedeCJFeldmanRGWoltersECKwakkelGWagenaarRCEfficacy of a physical therapy program in patients with Parkinsons disease: a randomized controlled trialArch Phys Med Rehabil200586462663215827910
   PubMed Web of Science ®Google Scholar
• MorrisMEIansekRKirkwoodBA randomized controlled trial of movement strategies compared with exercise for people with Parkinson’s diseaseMov Disord2009241647118942100
   PubMed Web of Science ®Google Scholar
• BarbeMTCepuranFAmarellMSchoenauETimmermannLLong-term effect of robot-assisted treadmill walking reduces freezing of gait in Parkinson’s disease patients: a pilot studyJ Neurol2013260129629823070468
   PubMed Web of Science ®Google Scholar
• TomlinsonCLPatelSMeekCPhysiotherapy versus placebo or no intervention in Parkinson’s diseaseCochrane Database Syst Rev20127CD00281722786482
   PubMed Web of Science ®Google Scholar
• ChrispPMammenGJSorkinEMSelegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson’s diseaseDrugs Aging1991132282481794016
   PubMedGoogle Scholar
• YoudimMBBar AmOYogev-FalachMRasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transitionJ Neurosci Res2005791–217217915573406
   PubMed Web of Science ®Google Scholar
• ZouLJankovicJRoweDBXieWAppelSHLeWNeuroprotection by pramipexole against dopamine- and levodopa-induced cytotoxicityLife Sci199964151275128510227583
   PubMed Web of Science ®Google Scholar
• BealMFMatthewsRTTielemanAShultsCWCoenzyme Q10 attenuates the 1-methyl-4-phenyl-1,2,3,tetrahydropyridine (MPTP) induced loss of striatal dopamine and dopaminergic axons in aged miceBrain Res199878311091149479058
   PubMed Web of Science ®Google Scholar
• OlanowCWRascolOHauserRA double-blind, delayed-start trial of rasagiline in Parkinson’s diseaseN Engl J Med2009361131268127819776408
   PubMed Web of Science ®Google Scholar
• Parkinson Study GroupA controlled, randomized, delayed-start study of rasagiline in early Parkinson diseaseArch Neurol200461456156615096406
   PubMed Web of Science ®Google Scholar
• SchapiraAHAlbrechtSBaronePRationale for delayed-start study of pramipexole in Parkinson’s disease: the PROUD studyMov Disord201025111627163220544810
   PubMed Web of Science ®Google Scholar
• HartRGPearceLARavinaBMYalthoTCMarlerJRNeuroprotection trials in Parkinson’s disease: systematic reviewMov Disord200924564765419117366
   PubMed Web of Science ®Google Scholar
• GoetzCGPoeweWRascolOSampaioCEvidence-based medical review update: pharmacological and surgical treatments of Parkinson’s disease: 2001 to 2004Mov Disord200520552353915818599
   PubMed Web of Science ®Google Scholar
• AdlerCHSingerCO’BrienCRandomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa–carbidopa. Tolcapone Fluctuator Study Group IIIArch Neurol1998558108910959708959
   PubMedGoogle Scholar
• DeaneKHSpiekerSClarkeCECatechol-O-methyltransferase inhibitors for levodopa-induced complications in Parkinson’s diseaseCochrane Database Syst Rev20044CD00455415495119
   PubMedGoogle Scholar
• KurthMCAdlerCHHilaireMSTolcapone improves motor function and reduces levodopa requirement in patients with Parkinson’s disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group INeurology199748181879008498
   PubMed Web of Science ®Google Scholar
• FahnSOakesDShoulsonILevodopa and the progression of Parkinson’s diseaseN Engl J Med2004351242498250815590952
   PubMed Web of Science ®Google Scholar
• TalatiRBakerWLPatelAAReinhartKColemanCIAdding a dopamine agonist to preexisting levodopa therapy vs levodopa therapy alone in advanced Parkinson’s disease: a meta analysisInt J Clin Pract200963461362319222614
   PubMed Web of Science ®Google Scholar
• KvernmoTHoubenJSylteIReceptor-binding and pharmacokinetic properties of dopaminergic agonistsCurr Top Med Chem20088121049106718691132
   PubMed Web of Science ®Google Scholar
• FoxSHKatzenschlagerRLimSYThe Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson’s diseaseMov Disord201126Suppl 3S2S4122021173
   PubMed Web of Science ®Google Scholar
• MollerJCOertelWHKosterJPezzoliGProvincialiLLong-term efficacy and safety of pramipexole in advanced Parkinson’s disease: results from a European multicenter trialMov Disord200520560261015726540
   PubMed Web of Science ®Google Scholar
• HollowayRGShoulsonIFahnSPramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trialArch Neurol20046171044105315262734
   PubMedGoogle Scholar
• HauserRARascolOKorczynADTen-year follow-up of Parkinson’s disease patients randomized to initial therapy with ropinirole or levodopaMov Disord200722162409241717894339
   PubMed Web of Science ®Google Scholar
• OlanowCWWatkinsPBTolcapone: an efficacy and safety review (2007)Clin Neuropharmacol200730528729417909307
   PubMed Web of Science ®Google Scholar
• ReichmannHBoasJMacmahonDMyllylaVHakalaAReinikainenKEfficacy of combining levodopa with entacapone on quality of life and activities of daily living in patients experiencing wearing-off type fluctuationsActa Neurol Scand20051111212815595934
   PubMed Web of Science ®Google Scholar
• SnowBJMacdonaldLMcauleyDWallisWThe effect of amantadine on levodopa-induced dyskinesias in Parkinson’s disease: a double-blind, placebo-controlled studyClin Neuropharmacol2000232828510803797
   PubMed Web of Science ®Google Scholar
• LugingerEWenningGKBoschSPoeweWBeneficial effects of amantadine on L-dopa-induced dyskinesias in Parkinson’s diseaseMov Disord200015587387811009193
   PubMed Web of Science ®Google Scholar
• HauserRACantillonMPourcherEPreladenant in patients with Parkinson’s disease and motor fluctuations: a phase 2, double-blind, randomised trialLancet Neurol201110322122921315654
   PubMed Web of Science ®Google Scholar
• HodgsonRABedardPJVartyGBPreladenant, a selective A(2A) receptor antagonist, is active in primate models of movement disordersExp Neurol2010225238439020655910
   PubMed Web of Science ®Google Scholar
• PostumaRBLangAEMunhozRPCaffeine for treatment of Parkinson disease: a randomized controlled trialNeurology201279765165822855866
   PubMed Web of Science ®Google Scholar
• OlanowCWObesoJAStocchiFDrug insight: continuous dopaminergic stimulation in the treatment of Parkinson’s diseaseNat Clin Pract Neurol20062738239216932589
   PubMedGoogle Scholar
• OndoWGSethiKDKricorianGSelegiline orally disintegrating tablets in patients with Parkinson disease and “wearing off” symptomsClin Neuropharmacol200730529530017909308
   PubMed Web of Science ®Google Scholar
• CrosbyNDeaneKHClarkeCEAmantadine in Parkinson’s diseaseCochrane Database Syst Rev20031CD00346812535476
   PubMedGoogle Scholar
• PedrosaDJReckCFlorinEEssential tremor and tremor in Parkinson’s disease are associated with distinct “tremor clusters” in the ventral thalamusExp Neurol2012237243544322809566
   PubMed Web of Science ®Google Scholar
• HelmichRCJanssenMJOyenWJBloemBRToniIPallidal dysfunction drives a cerebellothalamic circuit into Parkinson tremorAnn Neurol201169226928121387372
   PubMed Web of Science ®Google Scholar
• Parkinson Study GroupLow-dose clozapine for the treatment of drug-induced psychosis in Parkinson’s diseaseN Engl J Med19993401075776310072410
   PubMed Web of Science ®Google Scholar
• HarizMIKrackPAleschFMulticentre European study of thalamic stimulation for parkinsonian tremor: a 6 year follow-upJ Neurol Neurosurg Psychiatry200879669469917898034
   PubMed Web of Science ®Google Scholar
• PillonBDuboisBBonnetAMCognitive slowing in Parkinson’s disease fails to respond to levodopa treatment: the 15-objects testNeurology19893967627682725868
   PubMed Web of Science ®Google Scholar
• LevyGLouisEDCoteLContribution of aging to the severity of different motor signs in Parkinson diseaseArch Neurol200562346747215767513
   PubMedGoogle Scholar
• RahmanSGriffinHJQuinnNPJahanshahiMThe factors that induce or overcome freezing of gait in Parkinson’s diseaseBehav Neurol200819312713618641432
   PubMed Web of Science ®Google Scholar
• NieuwboerAKwakkelGRochesterLCueing training in the home improves gait-related mobility in Parkinson’s disease: the RESCUE trialJ Neurol Neurosurg Psychiatry200778213414017229744
   PubMed Web of Science ®Google Scholar
• AriasPCudeiroJEffect of rhythmic auditory stimulation on gait in parkinsonian patients with and without freezing of gaitPLoS One201053e967520339591
   PubMed Web of Science ®Google Scholar
• NieuwboerABakerKWillemsAMThe short-term effects of different cueing modalities on turn speed in people with Parkinson’s diseaseNeurorehabil Neural Repair200923883183619491396
   PubMed Web of Science ®Google Scholar
• NieuwboerACueing for freezing of gait in patients with Parkinson’s disease: a rehabilitation perspectiveMov Disord200823Suppl 2S475S48118668619
   PubMed Web of Science ®Google Scholar
• AllenNECanningCGSherringtonCThe effects of an exercise program on fall risk factors in people with Parkinson’s disease: a randomized controlled trialMov Disord20102591217122520629134
   PubMed Web of Science ®Google Scholar
• GiladiNMcDermottMPFahnSFreezing of gait in PD: prospective assessment in the DATATOP cohortNeurology200156121712172111425939
   PubMed Web of Science ®Google Scholar
• JankovicJLong-term study of pergolide in Parkinson’s diseaseNeurology19853532962993974887
   PubMed Web of Science ®Google Scholar
• GiladiNMedical treatment of freezing of gaitMov Disord200823Suppl 2S482S48818668620
   PubMed Web of Science ®Google Scholar
• FerrayeMUDebuBFraixVEffects of subthalamic nucleus stimulation and levodopa on freezing of gait in Parkinson diseaseNeurology20087016 Pt 21431143718413568
   PubMed Web of Science ®Google Scholar
• DavisJTLyonsKEPahwaRFreezing of gait after bilateral subthalamic nucleus stimulation for Parkinson’s diseaseClin Neurol Neurosurg2006108546146416139421
   PubMed Web of Science ®Google Scholar
• MoreauCDefebvreLDesteeASTN-DBS frequency effects on freezing of gait in advanced Parkinson diseaseNeurology2008712808418420482
   PubMed Web of Science ®Google Scholar
• FerrayeMUDebuBFraixVEffects of pedunculopontine nucleus area stimulation on gait disorders in Parkinson’s diseaseBrain2010133Pt 120521419773356
   PubMed Web of Science ®Google Scholar
• FinstererJStroblWPresentation, etiology, diagnosis, and management of camptocormiaEur Neurol20106411820634620
   PubMed Web of Science ®Google Scholar
• JankovicJCamptocormia, head drop and other bent spine syndromes: heterogeneous etiology and pathogenesis of parkinsonian deformitiesMov Disord201025552752820425791
   PubMed Web of Science ®Google Scholar
• ClaassenDOJosephsKAAhlskogJESilberMHTippmann-PeikertMBoeveBFREM sleep behavior disorder preceding other aspects of synucleinopathies by up to half a centuryNeurology201075649449920668263
   PubMed Web of Science ®Google Scholar
• OlsonEJBoeveBFSilberMHRapid eye movement sleep behaviour disorder: demographic, clinical and laboratory findings in 93 casesBrain2000123Pt 233133910648440
   PubMed Web of Science ®Google Scholar
• SeppiKWeintraubDCoelhoMThe Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson’s diseaseMov Disord201126Suppl 3S42S8022021174
   PubMed Web of Science ®Google Scholar
• AuroraRNKristoDABistaSRThe treatment of restless legs syndrome and periodic limb movement disorder in adults – an update for 2012: practice parameters with an evidence-based systematic review and meta-analyses: an American Academy of Sleep Medicine Clinical Practice GuidelineSleep20123581039106222851801
   PubMed Web of Science ®Google Scholar
• OertelWTrenkwalderCBenesHLong-term safety and efficacy of rotigotine transdermal patch for moderate-to-severe idiopathic restless legs syndrome: a 5-year open-label extension studyLancet Neurol201110871072021705273
   PubMed Web of Science ®Google Scholar
• ArnulfIBejjaniBPGarmaLImprovement of sleep architecture in PD with subthalamic nucleus stimulationNeurology200055111732173411113233
   PubMed Web of Science ®Google Scholar
• IranzoAValldeoriolaFSantamariaJTolosaERumiaJSleep symptoms and polysomnographic architecture in advanced Parkinson’s disease after chronic bilateral subthalamic stimulationJ Neurol Neurosurg Psychiatry200272566166411971059
   PubMed Web of Science ®Google Scholar
• MonacaCOzsancakCJacquessonJMEffects of bilateral subthalamic stimulation on sleep in Parkinson’s diseaseJ Neurol2004251221421814991357
   PubMed Web of Science ®Google Scholar
• KediaSMoroETagliatiMLangAEKumarREmergence of restless legs syndrome during subthalamic stimulation for Parkinson diseaseNeurology200463122410241215623715
   PubMed Web of Science ®Google Scholar
• ArnulfIBejjaniBPGarmaLEffect of low and high frequency thalamic stimulation on sleep in patients with Parkinson’s disease and essential tremorJ Sleep Res200091556210733690
   PubMed Web of Science ®Google Scholar
• LarsenJPTandbergESleep disorders in patients with Parkinson’s disease: epidemiology and managementCNS Drugs200115426727511463132
   PubMed Web of Science ®Google Scholar
• WakabayashiKTakahashiHOhamaETakedaSIkutaFLewy bodies in the visceral autonomic nervous system in Parkinson’s diseaseAdv Neurol1993606096128420198
   PubMedGoogle Scholar
• LahrmannHCortelliPHilzMMathiasCJStruhalWTassinariMEFNS guidelines on the diagnosis and management of orthostatic hypotensionEur J Neurol200613993093616930356
   PubMed Web of Science ®Google Scholar
• ArandaBCramerPEffects of apomorphine and L-dopa on the parkinsonian bladderNeurourol Urodyn19931232032098330043
   PubMed Web of Science ®Google Scholar
• ChristmasTJKempsterPAChappleCRRole of subcutaneous apomorphine in parkinsonian voiding dysfunctionLancet198828626–8627145114532904571
   PubMed Web of Science ®Google Scholar
• SoykanISarosiekIShifflettJWootenGFMcCallumRWEffect of chronic oral domperidone therapy on gastrointestinal symptoms and gastric emptying in patients with Parkinson’s diseaseMov Disord19971269529579399220
   PubMed Web of Science ®Google Scholar
• RestivoDAPalmeriAMarchese-RagonaRBotulinum toxin for cricopharyngeal dysfunction in Parkinson’s diseaseN Engl J Med2002346151174117511948283
   PubMed Web of Science ®Google Scholar
• El SharkawiARamigLLogemannJASwallowing and voice effects of Lee Silverman Voice Treatment (LSVT): a pilot studyJ Neurol Neurosurg Psychiatry2002721313611784821
   PubMed Web of Science ®Google Scholar
• BrigantiASaloniaAGallinaADrug insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunctionNat Clin Pract Urol20052523924716474835
   PubMedGoogle Scholar
• LawrenceADEvansAHLeesAJCompulsive use of dopamine replacement therapy in Parkinson’s disease: reward systems gone awry?Lancet Neurol200321059560414505581
   PubMed Web of Science ®Google Scholar
• EvansAHLeesAJDopamine dysregulation syndrome in Parkinson’s diseaseCurr Opin Neurol200417439339815247533
   PubMed Web of Science ®Google Scholar
• ThomasABonanniLGambiFDi IorioAOnofrjMPathological gambling in Parkinson disease is reduced by amantadineAnn Neurol201068340040420687121
   PubMed Web of Science ®Google Scholar
• CummingsJLBehavioral complications of drug treatment of Parkinson’s diseaseJ Am Geriatr Soc19913977087162061539
   PubMed Web of Science ®Google Scholar
• HendersonMJMellersJDCPsychosis in Parkinson’s disease: “between a rock and a hard place.”Int Rev Psychiatry2000124319334
   Web of Science ®Google Scholar
• Sanchez-RamosJROrtollRPaulsonGWVisual hallucinations associated with Parkinson diseaseArch Neurol19965312126512688970453
   PubMed Web of Science ®Google Scholar
• PacchettiCManniRZangagliaRRelationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson’s diseaseMov Disord200520111439144816028215
   PubMed Web of Science ®Google Scholar
• AarslandDLarsenJPCumminsJLLaakeKPrevalence and clinical correlates of psychotic symptoms in Parkinson disease: a community-based studyArch Neurol199956559560110328255
   PubMedGoogle Scholar
• FenelonGMahieuxFHuonRZieglerMHallucinations in Parkinson’s disease: prevalence, phenomenology and risk factorsBrain2000123Pt 473374510734005
   PubMed Web of Science ®Google Scholar
• AarslandDBallardCLarsenJPMcKeithIA comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson’s disease with and without dementiaInt J Geriatr Psychiatry200116552853611376470
   PubMed Web of Science ®Google Scholar
• MarshLWilliamsJRRoccoMGrillSMunroCDawsonTMPsychiatric comorbidities in patients with Parkinson disease and psychosisNeurology200463229330015277623
   PubMed Web of Science ®Google Scholar
• FactorSAFriedmanJHLannonMCOakesDBourgeoisKClozapine for the treatment of drug-induced psychosis in Parkinson’s disease: results of the 12 week open label extension in the PSYCLOPS trialMov Disord200116113513911215574
   PubMed Web of Science ®Google Scholar
• MorganteLEpifanioASpinaEQuetiapine and clozapine in parkinsonian patients with dopaminergic psychosisClin Neuropharmacol200427415315615319699
   PubMed Web of Science ®Google Scholar
• OndoWGTintnerRVoungKDLaiDRingholzGDouble-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson’s diseaseMov Disord200520895896315800937
   PubMed Web of Science ®Google Scholar
• MerimsDBalasMPeretzCShabtaiHGiladiNRater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson’s disease psychosisClin Neuropharmacol200629633133717095896
   PubMed Web of Science ®Google Scholar
• BergmanJLernerVSuccessful use of donepezil for the treatment of psychotic symptoms in patients with Parkinson’s diseaseClin Neuropharmacol200225210711011981238
   PubMed Web of Science ®Google Scholar
• AarslandDHutchinsonMLarsenJPCognitive, psychiatric and motor response to galantamine in Parkinson’s disease with dementiaInt J Geriatr Psychiatry2003181093794114533126
   PubMed Web of Science ®Google Scholar
• BohnenNIKauferDIIvancoLSCortical cholinergic function is more severely affected in parkinsonian dementia than in Alzheimer disease: an in vivo positron emission tomographic studyArch Neurol200360121745174814676050
   PubMed Web of Science ®Google Scholar
• EmreMAarslandDAlbaneseARivastigmine for dementia associated with Parkinson’s diseaseN Engl J Med2004351242509251815590953
   PubMed Web of Science ®Google Scholar
• AarslandDBallardCWalkerZMemantine in patients with Parkinson’s disease dementia or dementia with Lewy bodies: a double-blind, placebo-controlled, multicentre trialLancet Neurol20098761361819520613
   PubMed Web of Science ®Google Scholar
• LeroiIOvershottRByrneEJDanielEBurnsARandomized controlled trial of memantine in dementia associated with Parkinson’s diseaseMov Disord20092481217122119370737
   PubMed Web of Science ®Google Scholar
• LemkeMRFuchsGGemendeIDepression and Parkinson’s diseaseJ Neurol2004251Suppl 6VI/24VI/27
   Web of Science ®Google Scholar
• Global Parkinson’s Disease Survey Steering CommitteeFactors impacting on quality of life in Parkinson’s disease: results from an international surveyMov Disord2002171606711835440
   PubMed Web of Science ®Google Scholar
• KuopioAMMarttilaRJHeleniusHToivonenMRinneUKThe quality of life in Parkinson’s diseaseMov Disord200015221622310752569
   PubMed Web of Science ®Google Scholar
• SchragAJahanshahiMQuinnNWhat contributes to quality of life in patients with Parkinson’s disease?J Neurol Neurosurg Psychiatry200069330831210945804
   PubMed Web of Science ®Google Scholar
• RemyPDoderMLeesATurjanskiNBrooksDDepression in Parkinson’s disease: loss of dopamine and noradrenaline innervation in the limbic systemBrain2005128Pt 61314132215716302
   PubMed Web of Science ®Google Scholar
• MajJRogozZSkuzaGKolodziejczykKThe behavioural effects of pramipexole, a novel dopamine receptor agonistEur J Pharmacol1997324131379137910
   PubMed Web of Science ®Google Scholar
• WillnerPLappasSCheetaSMuscatRReversal of stress-induced anhedonia by the dopamine receptor agonist, pramipexolePsychopharmacology (Berl)199411544544627871089
   PubMed Web of Science ®Google Scholar
• LemkeMRBrechtHMKoesterJKrausPHReichmannHAnhedonia, depression, and motor functioning in Parkinson’s disease during treatment with pramipexoleJ Neuropsychiatry Clin Neurosci200517221422015939976
   PubMed Web of Science ®Google Scholar
• AntoniniATolosaEApomorphine and levodopa infusion therapies for advanced Parkinson’s disease: selection criteria and patient managementExpert Rev Neurother20099685986719496689
   PubMed Web of Science ®Google Scholar
• LundqvistCContinuous levodopa for advanced Parkinson’s diseaseNeuropsychiatr Dis Treat20073333534819300565
   PubMedGoogle Scholar
• DevosDPatient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson’s diseaseMov Disord2009247993100019253412
   PubMed Web of Science ®Google Scholar
• PoeweWKleedorferBWagnerMBoschSScheloskyLContinuous subcutaneous apomorphine infusions for fluctuating Parkinson’s disease. Long-term follow-up in 18 patientsAdv Neurol1993606566598420206
   PubMedGoogle Scholar
• StibeCMLeesAJKempsterPASternGMSubcutaneous apomorphine in parkinsonian on–off oscillationsLancet1988185824034062893200
   PubMed Web of Science ®Google Scholar
• FrankelJPLeesAJKempsterPASternGMSubcutaneous apomorphine in the treatment of Parkinson’s diseaseJ Neurol Neurosurg Psychiatry1990532961012313313
   PubMed Web of Science ®Google Scholar
• McIntyreCCSavastaMKerkerian-Le GoffLVitekJLUncovering the mechanism(s) of action of deep brain stimulation: activation, inhibition, or bothClin Neurophysiol200411561239124815134690
   PubMed Web of Science ®Google Scholar
• AllertNLehrkeRSturmVVolkmannJSecondary failure after ten years of pallidal neurostimulation in a patient with advanced Parkinson’s diseaseJ Neural Transm2010117334935120069437
   PubMed Web of Science ®Google Scholar
• VolkmannJDeep brain stimulation for the treatment of Parkinson’s diseaseJ Clin Neurophysiol200421161715097290
   PubMed Web of Science ®Google Scholar
• VolkmannJDanielsCWittKNeuropsychiatric effects of subthalamic neurostimulation in Parkinson diseaseNat Rev Neurol20106948749820680036
   PubMed Web of Science ®Google Scholar
• VoonVKrackPLangAEA multicentre study on suicide outcomes following subthalamic stimulation for Parkinson’s diseaseBrain2008131Pt 102720272818941146
   PubMed Web of Science ®Google Scholar
• DanielsCKrackPVolkmannJRisk factors for executive dysfunction after subthalamic nucleus stimulation in Parkinson’s diseaseMov Disord201025111583158920589868
   PubMed Web of Science ®Google Scholar
• YorkMKWildeEASimpsonRJankovicJRelationship between neuropsychological outcome and DBS surgical trajectory and electrode locationJ Neurol Sci20092871–215917119767016
   PubMed Web of Science ®Google Scholar
• WeaverFMFollettKASternMRandomized trial of deep brain stimulation for Parkinson disease: thirty-six-month outcomesNeurology2012791556522722632
   PubMed Web of Science ®Google Scholar
• KrackPDostrovskyJIlinskyISurgery of the motor thalamus: problems with the present nomenclaturesMov Disord200217Suppl 3S2S811948749
   PubMed Web of Science ®Google Scholar
• WojteckiLTimmermannLJorgensSFrequency-dependent reciprocal modulation of verbal fluency and motor functions in subthalamic deep brain stimulationArch Neurol20066391273127616966504
   PubMedGoogle Scholar
• MasonAIlinskyIAMaldonadoSKultas-IlinskyKThalamic terminal fields of individual axons from the ventral part of the dentate nucleus of the cerebellum in Macaca mulattaJ Comp Neurol2000421341242810813796
   PubMed Web of Science ®Google Scholar
• HamaniCMoroELozanoAMThe pedunculopontine nucleus as a target for deep brain stimulationJ Neural Transm2011118101461146821194002
   PubMed Web of Science ®Google Scholar
• StefaniALozanoAMPeppeABilateral deep brain stimulation of the pedunculopontine and subthalamic nuclei in severe Parkinson’s diseaseBrain2007130Pt 61596160717251240
   PubMed Web of Science ®Google Scholar
• CostaACarlesimoGACaltagironeCEffects of deep brain stimulation of the peduncolopontine area on working memory tasks in patients with Parkinson’s diseaseParkinsonism Relat Disord2010161646719502095
   PubMed Web of Science ®Google Scholar
• StefaniAPierantozziMCeravoloRBrusaLGalatiSStanzionePDeep brain stimulation of pedunculopontine tegmental nucleus (PPTg) promotes cognitive and metabolic changes: a target-specific effect or response to a low-frequency pattern of stimulation?Clin EEG Neurosci2010412828620521490
   PubMed Web of Science ®Google Scholar
• ZahodneLBOkunMSFooteKDGreater improvement in quality of life following unilateral deep brain stimulation surgery in the globus pallidus as compared to the subthalamic nucleusJ Neurol200925681321132919363633
   PubMed Web of Science ®Google Scholar
• FollettKAWeaverFMSternMPallidal versus subthalamic deep-brain stimulation for Parkinson’s diseaseN Engl J Med2010362222077209120519680
   PubMed Web of Science ®Google Scholar
• OkunMSFernandezHHWuSSCognition and mood in Parkinson’s disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the COMPARE trialAnn Neurol200965558659519288469
   PubMed Web of Science ®Google Scholar
• CharlesPDGillCEDavisTLKonradPEBenabidALIs deep brain stimulation neuroprotective if applied early in the course of PD?Nat Clin Pract Neurol20084842442618594505
   PubMedGoogle Scholar
• DeuschlGSchade-BrittingerCKrackPA randomized trial of deep-brain stimulation for Parkinson’s diseaseN Engl J Med2006355989690816943402
   PubMed Web of Science ®Google Scholar
• WeaverFFollettKHurKIppolitoDSternMDeep brain stimulation in Parkinson disease: a metaanalysis of patient outcomesJ Neurosurg2005103695696716381181
   PubMed Web of Science ®Google Scholar
• WilliamsAGillSVarmaTDeep brain stimulation plus best medical therapy versus best medical therapy alone for advanced Parkinson’s disease (PD SURG trial): a randomised, open-label trialLancet Neurol20109658159120434403
   PubMed Web of Science ®Google Scholar
• RascolODuboisBCaldasACSennSDel SignoreSLeesAEarly piribedil monotherapy of Parkinson’s disease: a planned seven-month report of the REGAIN studyMov Disord200621122110211517013922
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group CALM Cohort InvestigatorsLong-term effect of initiating pramipexole vs levodopa in early Parkinson diseaseArch Neurol200966556357019433655
   PubMedGoogle Scholar
• BaronePScarzellaLMarconiRPramipexole versus sertraline in the treatment of depression in Parkinson’s disease: a national multicenter parallel-group randomized studyJ Neurol2006253560160716607468
   PubMed Web of Science ®Google Scholar
• PahwaRLyonsKEOptions in the treatment of motor fluctuations and dyskinesias in Parkinson’s disease: a brief reviewNeurol Clin200422Suppl 3S35S5215501365
   PubMed Web of Science ®Google Scholar
• WolfESeppiKKatzenschlagerRLong-term antidyskinetic efficacy of amantadine in Parkinson’s diseaseMov Disord201025101357136320198649
   PubMed Web of Science ®Google Scholar
• DurifFDebillyBGalitzkyMClozapine improves dyskinesias in Parkinson disease: a double-blind, placebo-controlled studyNeurology200462338138814872017
   PubMed Web of Science ®Google Scholar
• SpiekerSEisebittRBreitSTremorlytic activity of budipine in Parkinson’s diseaseClin Neuropharmacol199922211511910202609
   PubMed Web of Science ®Google Scholar
• FriedmanJHKollerWCLannonMCBusenbarkKSwanson-HylandESmithDBenztropine versus clozapine for the treatment of tremor in Parkinson’s diseaseNeurology1997484107710819109903
   PubMed Web of Science ®Google Scholar
• AndersonKNShneersonJMDrug treatment of REM sleep behavior disorder: the use of drug therapies other than clonazepamJ Clin Sleep Med20095323523919960644
   PubMed Web of Science ®Google Scholar
• StocchiFBarbatoLNorderaGBerardelliARuggieriSSleep disorders in Parkinson’s diseaseJ Neurol1998245Suppl 1S15S189617717
   PubMed Web of Science ®Google Scholar
• Ferini-StrambiLAarskogDPartinenMEffect of pramipexole on RLS symptoms and sleep: a randomized, double-blind, placebo-controlled trialSleep Med20089887488118952497
   PubMed Web of Science ®Google Scholar
• MontagnaPHornyakMUlfbergJRandomized trial of pramipexole for patients with restless legs syndrome (RLS) and RLS-related impairment of moodSleep Med2011121344020965780
   PubMed Web of Science ®Google Scholar
• OertelWHStiasny-KolsterKBergtholdtBEfficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (effect-RLS study)Mov Disord200722221321917133582
   PubMed Web of Science ®Google Scholar
• BoganRKFryJMSchmidtMHCarsonSWRitchieSYRopinirole in the treatment of patients with restless legs syndrome: a US-based randomized, double-blind, placebo-controlled clinical trialMayo Clin Proc2006811172716438474
   PubMed Web of Science ®Google Scholar
• TrenkwalderCGarcia-BorregueroDMontagnaPRopinirole in the treatment of restless legs syndrome: results from the TREAT RLS 1 study, a 12 week, randomised, placebo controlled study in 10 European countriesJ Neurol Neurosurg Psychiatry2004751929714707315
   PubMed Web of Science ®Google Scholar
• HeningWAAllenRPOndoWGRotigotine improves restless legs syndrome: a 6-month randomized, double-blind, placebo-controlled trial in the United StatesMov Disord201025111675168320629075
   PubMed Web of Science ®Google Scholar
• OertelWHBenesHGarcia-BorregueroDRotigotine transdermal patch in moderate to severe idiopathic restless legs syndrome: a randomized, placebo-controlled polysomnographic studySleep Med201011984885620813583
   PubMed Web of Science ®Google Scholar
• KushidaCABeckerPMEllenbogenALCanafaxDMBarrettRWRandomized, double-blind, placebo-controlled study of XP13512/GSK1838262 in patients with RLSNeurology200972543944619188575
   PubMed Web of Science ®Google Scholar
• KushidaCAWaltersASBeckerPA randomized, double-blind, placebo-controlled, crossover study of XP13512/GSK1838262 in the treatment of patients with primary restless legs syndromeSleep200932215916819238802
   PubMed Web of Science ®Google Scholar
• LeeDOZimanRBPerkinsATPocetaJSWaltersASBarrettRWA randomized, double-blind, placebo-controlled study to assess the efficacy and tolerability of gabapentin enacarbil in subjects with restless legs syndromeJ Clin Sleep Med20117328229221677899
   PubMed Web of Science ®Google Scholar
• WaltersASOndoWGKushidaCAGabapentin enacarbil in restless legs syndrome: a phase 2b, 2-week, randomized, double-blind, placebo-controlled trialClin Neuropharmacol200932631132019667976
   PubMed Web of Science ®Google Scholar
• WinkelmanJWBoganRKSchmidtMHHudsonJDDeRossettSEHill-ZabalaCERandomized polysomnography study of gabapentin enacarbil in subjects with restless legs syndromeMov Disord201126112065207221611981
   PubMed Web of Science ®Google Scholar
• HoglBPaulusWClarenbachPTrenkwalderCRestless legs syndrome: diagnostic assessment and the advantages and risks of dopaminergic treatmentJ Neurol2006253Suppl 4IV22IV2816944353
   PubMedGoogle Scholar
• Garcia-BorregueroDLarrosaOde la LlaveYVergerKMasramonXHernandezGTreatment of restless legs syndrome with gabapentin: a double-blind, cross-over studyNeurology200259101573157912451200
   PubMed Web of Science ®Google Scholar
• HappeSSauterCKloschGSaletuBZeitlhoferJGabapentin versus ropinirole in the treatment of idiopathic restless legs syndromeNeuropsychobiology2003482828614504416
   PubMed Web of Science ®Google Scholar
• SchofferKLHendersonRDO’MaleyKO’SullivanJDNonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson’s diseaseMov Disord200722111543154917557339
   PubMed Web of Science ®Google Scholar
• ZangagliaRMartignoniEGloriosoMMacrogol for the treatment of constipation in Parkinson’s disease. A randomized placebo-controlled studyMov Disord20072291239124417566120
   PubMed Web of Science ®Google Scholar
• HussainIFBradyCMSwinnMJMathiasCJFowlerCJTreatment of erectile dysfunction with sildenafil citrate (Viagra) in parkinsonism due to Parkinson’s disease or multiple system atrophy with observations on orthostatic hypotensionJ Neurol Neurosurg Psychiatry200171337137411511713
   PubMed Web of Science ®Google Scholar
• FernandezHHOkunMSRodriguezRLQuetiapine improves visual hallucinations in Parkinson disease but not through normalization of sleep architecture: results from a double-blind clinical-polysomnography studyInt J Neurosci2009119122196220519916848
   PubMed Web of Science ®Google Scholar
• RabeyJMProkhorovTMiniovitzADobronevskyEKleinCEffect of quetiapine in psychotic Parkinson’s disease patients: a double-blind labeled study of 3 months’ durationMov Disord200722331331817034006
   PubMed Web of Science ®Google Scholar
• ShotboltPSamuelMDavidAQuetiapine in the treatment of psychosis in Parkinson’s diseaseTher Adv Neurol Disord20103633935021179595
   PubMedGoogle Scholar
• EmreMTsolakiMBonuccelliUMemantine for patients with Parkinson’s disease dementia or dementia with Lewy bodies: a randomised, double-blind, placebo-controlled trialLancet Neurol201091096997720729148
   PubMed Web of Science ®Google Scholar
• BaronePPoeweWAlbrechtSPramipexole for the treatment of depressive symptoms in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled trialLancet Neurol20109657358020452823
   PubMed Web of Science ®Google Scholar
• RektorovaIRektorIBaresMPramipexole and pergolide in the treatment of depression in Parkinson’s disease: a national multicentre prospective randomized studyEur J Neurol200310439940612823492
   PubMed Web of Science ®Google Scholar
• DevosDDujardinKPoirotIComparison of desipramine and citalopram treatments for depression in Parkinson’s disease: a double-blind, randomized, placebo-controlled studyMov Disord200823685085718311826
   PubMed Web of Science ®Google Scholar
• MenzaMDobkinRDMarinHA controlled trial of antidepressants in patients with Parkinson disease and depressionNeurology2009721088689219092112
   PubMed Web of Science ®Google Scholar
• EggertKOertelWHReichmannHParkinson-Syndrome: Diagnostik und TherapieLeitlinien für Diagnostik und Therapie in der NeurologieDienerHCWeimarC Leitlinien für Diagnostik und Therapie in der Neurologie 5 überarb AuflageStuttgartThieme201282112 [German]
   Google Scholar
• SchuepbachWMRauJKnudsenKEARLYSTIM Study GroupNeurostimulation for Parkinson’s disease with early motor complicationsN Engl J Med20132143687610622 10.1056/NEJMoa120515823406026
   PubMed Web of Science ®Google Scholar